NCT00121199View on ClinicalTrials.gov

Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Contiguous Stage II Adult Diffuse Large Cell LymphomaNoncontiguous Stage II Adult Diffuse Large Cell LymphomaStage III Adult Diffuse Large Cell LymphomaStage IV Adult Diffuse Large Cell Lymphoma

Interventions

BIOLOGICAL

rituximab

Given IV

BIOLOGICAL

bevacizumab

Given IV

DRUG

cyclophosphamide

Given IV

DRUG

doxorubicin hydrochloride

Given IV

DRUG

vincristine sulfate

Given IV

DRUG

prednisone

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

97239

SWOG, Portland

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00121199 - Combination Chemo, Rituximab, and Bevacizumab in Older Patients With Stage II-IV Diffuse Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter